vs
Pacira BioSciences, Inc.（PCRX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是STURM RUGER & CO INC的1.3倍（$196.9M vs $151.1M），Pacira BioSciences, Inc.同比增速更快（5.1% vs 3.6%），Pacira BioSciences, Inc.自由现金流更多（$43.5M vs $12.3M），过去两年Pacira BioSciences, Inc.的营收复合增速更高（8.5% vs 5.1%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
PCRX vs RGR — 直观对比
营收规模更大
PCRX
是对方的1.3倍
$151.1M
营收增速更快
PCRX
高出1.5%
3.6%
自由现金流更多
PCRX
多$31.1M
$12.3M
两年增速更快
PCRX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.9M | $151.1M |
| 净利润 | — | — |
| 毛利率 | 79.5% | 17.8% |
| 营业利润率 | 1.2% | 2.3% |
| 净利率 | — | — |
| 营收同比 | 5.1% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRGR
| Q4 25 | $196.9M | $151.1M | ||
| Q3 25 | $179.5M | $126.8M | ||
| Q2 25 | $181.1M | $132.5M | ||
| Q1 25 | $168.9M | $135.7M | ||
| Q4 24 | $187.3M | $145.8M | ||
| Q3 24 | $168.6M | $122.3M | ||
| Q2 24 | $178.0M | $130.8M | ||
| Q1 24 | $167.1M | $136.8M |
净利润PCRXRGR
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $1.6M | ||
| Q2 25 | $-4.8M | $-17.2M | ||
| Q1 25 | $4.8M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $4.7M | ||
| Q2 24 | $18.9M | $8.3M | ||
| Q1 24 | $9.0M | $7.1M |
毛利率PCRXRGR
| Q4 25 | 79.5% | 17.8% | ||
| Q3 25 | 80.9% | 15.1% | ||
| Q2 25 | 77.4% | 3.9% | ||
| Q1 25 | 79.7% | 22.0% | ||
| Q4 24 | 78.7% | 22.8% | ||
| Q3 24 | 76.9% | 18.5% | ||
| Q2 24 | 75.1% | 22.3% | ||
| Q1 24 | 71.6% | 21.5% |
营业利润率PCRXRGR
| Q4 25 | 1.2% | 2.3% | ||
| Q3 25 | 3.5% | -2.7% | ||
| Q2 25 | 4.7% | -15.6% | ||
| Q1 25 | 1.2% | 6.2% | ||
| Q4 24 | 13.2% | 7.8% | ||
| Q3 24 | -82.8% | 3.1% | ||
| Q2 24 | 15.9% | 6.9% | ||
| Q1 24 | 7.9% | 5.5% |
净利率PCRXRGR
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | 1.2% | ||
| Q2 25 | -2.7% | -13.0% | ||
| Q1 25 | 2.8% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | 3.9% | ||
| Q2 24 | 10.6% | 6.3% | ||
| Q1 24 | 5.4% | 5.2% |
每股收益（稀释后）PCRXRGR
| Q4 25 | $0.05 | $0.22 | ||
| Q3 25 | $0.12 | $0.10 | ||
| Q2 25 | $-0.11 | $-1.05 | ||
| Q1 25 | $0.10 | $0.46 | ||
| Q4 24 | $0.38 | $0.62 | ||
| Q3 24 | $-3.11 | $0.28 | ||
| Q2 24 | $0.39 | $0.47 | ||
| Q1 24 | $0.19 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.4M | $92.5M |
| 总债务越低越好 | $372.2M | — |
| 股东权益账面价值 | $693.1M | $283.8M |
| 总资产 | $1.3B | $342.0M |
| 负债/权益比越低杠杆越低 | 0.54× | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRGR
| Q4 25 | $238.4M | $92.5M | ||
| Q3 25 | $246.3M | $80.8M | ||
| Q2 25 | $445.9M | $101.4M | ||
| Q1 25 | $493.6M | $108.3M | ||
| Q4 24 | $484.6M | $105.5M | ||
| Q3 24 | $453.8M | $96.0M | ||
| Q2 24 | $404.2M | $105.6M | ||
| Q1 24 | $325.9M | $115.3M |
总债务PCRXRGR
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PCRXRGR
| Q4 25 | $693.1M | $283.8M | ||
| Q3 25 | $727.2M | $279.6M | ||
| Q2 25 | $757.8M | $289.3M | ||
| Q1 25 | $798.5M | $321.5M | ||
| Q4 24 | $778.3M | $319.6M | ||
| Q3 24 | $749.6M | $314.9M | ||
| Q2 24 | $879.3M | $321.5M | ||
| Q1 24 | $892.2M | $332.0M |
总资产PCRXRGR
| Q4 25 | $1.3B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.5B | $349.5M | ||
| Q1 25 | $1.6B | $379.0M | ||
| Q4 24 | $1.6B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.6B | $376.7M | ||
| Q1 24 | $1.6B | $385.0M |
负债/权益比PCRXRGR
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $43.5M | $12.3M |
| 自由现金流率自由现金流/营收 | 22.1% | 8.2% |
| 资本支出强度资本支出/营收 | 0.1% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $136.7M | $38.5M |
8季度趋势，按日历期对齐
经营现金流PCRXRGR
| Q4 25 | $43.7M | $15.5M | ||
| Q3 25 | $60.8M | $12.9M | ||
| Q2 25 | $12.0M | $14.7M | ||
| Q1 25 | $35.5M | $11.1M | ||
| Q4 24 | $33.1M | $20.0M | ||
| Q3 24 | $53.9M | $9.4M | ||
| Q2 24 | $53.2M | $18.7M | ||
| Q1 24 | $49.1M | $7.3M |
自由现金流PCRXRGR
| Q4 25 | $43.5M | $12.3M | ||
| Q3 25 | $57.0M | $7.0M | ||
| Q2 25 | $9.3M | $9.1M | ||
| Q1 25 | $26.9M | $10.0M | ||
| Q4 24 | $31.0M | $16.4M | ||
| Q3 24 | $49.8M | $2.6M | ||
| Q2 24 | $51.6M | $10.1M | ||
| Q1 24 | $46.3M | $5.6M |
自由现金流率PCRXRGR
| Q4 25 | 22.1% | 8.2% | ||
| Q3 25 | 31.7% | 5.5% | ||
| Q2 25 | 5.1% | 6.9% | ||
| Q1 25 | 15.9% | 7.4% | ||
| Q4 24 | 16.6% | 11.2% | ||
| Q3 24 | 29.6% | 2.1% | ||
| Q2 24 | 29.0% | 7.7% | ||
| Q1 24 | 27.7% | 4.1% |
资本支出强度PCRXRGR
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 2.2% | 4.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 5.1% | 0.8% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 2.4% | 5.5% | ||
| Q2 24 | 0.9% | 6.6% | ||
| Q1 24 | 1.7% | 1.3% |
现金转化率PCRXRGR
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 2.82× | 2.27× | ||
| Q1 24 | 5.47× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
